Thomson Medical Group (FRA:3H5) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


What is Thomson Medical Group Research & Development?

Thomson Medical Group FRA:3H5 Research & Development is €0.0 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Thomson Medical Group's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Thomson Medical Group  (FRA:3H5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Thomson Medical Group Research & Development Related Terms

Thomson Medical Group Research & Development Historical Data

* Premium members only.

The historical data trend for Thomson Medical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thomson Medical Group Research & Development Chart

Thomson Medical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Thomson Medical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Thomson Medical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Thomson Medical Group (FRA:3H5) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Thomson Medical Group and its competitors.
Is Thomson Medical Group's Research & Development too high?
Thomson Medical Group's current Research & Development is €0.0 Mil.
How does Thomson Medical Group's Research & Development compare to HCA and THC?
Thomson Medical Group's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Thomson Medical Group and its competitors. Thomson Medical Group's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thomson Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Thomson Medical Group (FRA:3H5) is currently considered Possible Value Trap. The stock's GF Value™ is €0.05, compared to a current price of €0.04 — trading 30% below its estimated fair value. The current Research & Development is €0.0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Thomson Medical Group (FRA:3H5), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thomson Medical Group Business Description

Other Exchanges A50:Singapore
Address 101 Thomson Road, No. 20-04/05, United Square, Singapore, SGP, 307591
Thomson Medical Group Ltd is a provider of healthcare services for women and children. Its segments include Hospital services; Specialised services and Investment holdings. It generates maximum revenue from the Specialised services segment. The specialised services segment includes services provided by fertility clinics, paediatric centres, cancer centre, cardiology centre, Chinese medicine, specialist skin centre and a pre-natal and clinical diagnostic laboratory and project-related services such as managing vaccination centres, COVID-19 Treatment Facilities and Transitional Care Facilities. It also includes a consumer business segment, comprising products and services. Geographically, it derives a majority of its revenue from Singapore.